Paolo Giorgi-Rossi

TL;DR: Data of large-scale randomised trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years, and provide 60-70% greater protection against invasive cervical carcinomas compared with cytology.

TL;DR: HPV-based screening is more effective than cytology in preventing invasive cervical cancer, by detecting persistent high-grade lesions earlier and providing a longer low-risk period, but in younger women, HPV screening leads to over-diagnosis of regressive CIN2.

TL;DR: HPV testing alone was more sensitive than conventional cytology among women 35-60 years old and HPV testing using Hybrid Capture 2 with a 2 pg/mL cutoff may be more appropriate than a 1 pg/ mL cutoff for primary cervical cancer screening.

TL;DR: The large relative sensitivity of HPV testing compared with conventional cytology and the difference between relative sensitivity during phases 1 and 2 suggests that there is frequent regression of CIN2+ that are detected by direct referral of younger HPV-positive women to colposcopy.

TL;DR: Liquid based cytology showed no statistically significant difference in sensitivity to conventional cytology for detection of cervical intraepithelial neoplasia of grade 2 or more, and more positive results were found, however, leading to a lower positive predictive value.